Impact of lenalidomide on the functional properties of human mesenchymal stromal cells

Experimental Hematology

Volumn 40, Issue 10, 2012, Pages 867-876

  Wobus, Manja ^a   Benath, Gwendolin ^a   Ferrer, Ruben A ^a   Wehner, Rebekka ^b   Schmitz, Marc ^b,c   Hofbauer, Lorenz C ^a   Rauner, Martina ^a   Ehninger, Gerhard ^a,c   Bornhäuser, Martin ^a,c   Platzbecker, Uwe ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

5' NUCLEOTIDASE; BETA1 INTEGRIN; LENALIDOMIDE; STROMAL CELL DERIVED FACTOR 1;

ANTIGEN EXPRESSION; ARTICLE; BONE MARROW; CELL ASSAY; CELL COMPARTMENTALIZATION; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IMMUNOMODULATION; IN VITRO STUDY; LYMPHOCYTE FUNCTION; LYMPHOCYTE PROLIFERATION; MESENCHYMAL STROMA CELL; PHENOTYPE; PRIORITY JOURNAL; SUPERNATANT; T LYMPHOCYTE;

5'-NUCLEOTIDASE; ADIPOGENESIS; ADULT; ANTIGENS, CD29; ANTINEOPLASTIC AGENTS; BONE MARROW CELLS; CELL DIFFERENTIATION; CHEMOKINE CXCL12; FEMALE; GPI-LINKED PROTEINS; HEMATOLOGIC NEOPLASMS; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; MIDDLE AGED; OSTEOGENESIS; THALIDOMIDE; TRANSPLANTATION, HOMOLOGOUS;

EID: 84866324411     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.06.004     Document Type: Article

References (30)

1. Pittenger M.F., Mackay A.M., Beck S.C., et al. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
2. Alakel N., Jing D., Muller K., et al. Direct contact with mesenchymal stromal cells affects migratory behavior and gene expression profile of CD133+ hematopoietic stem cells during ex vivo expansion. Exp Hematol 2009, 37:504-513.
3. Jing D., Fonseca A.V., Alakel N., et al. Hematopoietic stem cells in co-culture with mesenchymal stromal cells-modeling the niche compartments in vitro. Haematologica 2010, 95:542-550.
4. Uccelli A., Pistoia V., Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression?. Trends Immunol 2007, 28:219-226.
5. Zhao S., Wehner R., Bornhauser M., et al. Immunomodulatory properties of mesenchymal stromal cells and their therapeutic consequences for immune-mediated disorders. Stem Cells Dev 2010, 19:607-614.
6. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
7. Matsuoka A., Tochigi A., Kishimoto M., et al. Lenalidomide induces cell death in an MDS-derived cell line with deletion of chromosome 5q by inhibition of cytokinesis. Leukemia 2010, 24:748-755.
8. Davies F., Baz R. Lenalidomide mode of action: linking bench and clinical findings. Blood Rev 2010, 24(suppl 1):S13-S19.
9. Verhelle D., Corral L.G., Wong K., et al. Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells. Cancer Res 2007, 67:746-755.
10. Oswald J., Boxberger S., Jorgensen B., et al. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 2004, 22:377-384.
11. Hideshima T., Chauhan D., Shima Y., et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood 2000, 96:2943-2950.
12. Pellagatti A., Jadersten M., Forsblom A.M., et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A 2007, 104:11406-11411.
13. Jing D., Wobus M., Poitz D.M., et al. Oxygen tension plays a critical role in the hematopoietic microenvironment in vitro. Haematologica 2012, 97:331-339.
14. Hempel U., Hefti T., Kalbacova M., et al. Response of osteoblast-like SAOS-2 cells to zirconia ceramics with different surface topographies. Clin Oral Implants Res 2010, 21:174-181.
15. Lapidot T., Dar A., Kollet O. How do stem cells find their way home?. Blood 2005, 106:1901-1910.
16. Schecter J., Galili N., Raza A. MDS: Refining existing therapy through improved biologic insights. Blood Rev 2012, 26:73-80.
17. Trento C., Dazzi F. Mesenchymal stem cells and innate tolerance: biology and clinical applications. Swiss Med Wkly 2010, 140:w13121.
18. Glennie S., Soeiro I., Dyson P.J., Lam E.W., Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 2005, 105:2821-2827.
19. Varga G., Kiss J., Varkonyi J., et al. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes. Pathol Oncol Res 2007, 13:311-319.
20. Munemasa S., Sakai A., Kuroda Y., et al. Osteoprogenitor differentiation is not affected by immunomodulatory thalidomide analogs but is promoted by low bortezomib concentration, while both agents suppress osteoclast differentiation. Int J Oncol 2008, 33:129-136.
21. Pontikoglou C., Deschaseaux F., Sensebe L., Papadaki H.A. Bone marrow mesenchymal stem cells: biological properties and their role in hematopoiesis and hematopoietic stem cell transplantation. Stem Cell Rev 2011, 7:569-589.
22. Ode A., Kopf J., Kurtz A., et al. CD73 and CD29 concurrently mediate the mechanically induced decrease of migratory capacity of mesenchymal stromal cells. Eur Cell Mater 2011, 22:26-42.
23. Bodera P., Stankiewicz W. Immunomodulatory properties of thalidomide analogs: pomalidomide and lenalidomide, experimental and therapeutic applications. Recent Pat Endocr Metab Immune Drug Discov 2011, 5:192-196.
24. Chanan-Khan A.A., Cheson B.D. Lenalidomide for the treatment of B-cell malignancies. J Clin Oncol 2008, 20:26. 1544-1552.
25. Takedachi M., Oohara H., Smith B.J., et al. CD73-generated adenosine promotes osteoblast differentiation. J Cell Physiol 2012, 227:2622-2631.
26. Pellagatti A., Cazzola M., Giagounidis A., et al. Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells. Leukemia 2010, 24:756-764.
27. Wright N., de Lera T.L., Garcia-Moruja C., et al. Transforming growth factor-beta1 down-regulates expression of chemokine stromal cell-derived factor-1: functional consequences in cell migration and adhesion. Blood 2003, 102:1978-1984.
28. Matsuda M., Morita Y., Hanamoto H., et al. CD34+ progenitors from MDS patients are unresponsive to SDF-1, despite high levels of SDF-1 in bone marrow plasma. Leukemia 2004, 18:1038-1040.
29. Kumar S., Dispenzieri A., Lacy M.Q., et al. Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma. Leukemia 2007, 21:2035-2042.
30. Popat U., Saliba R., Thandi R., et al. Impairment of filgrastim-induced stem cell mobilization after prior lenalidomide in patients with multiple myeloma. Biol Blood Marrow Transplant 2009, 15:718-723.